Safety of and Immune Response to Cyclosporine A in Combination With Abacavir Sulfate, Lamivudine, and Zidovudine and Lopinavir/Ritonavir in Adults With Acute HIV Infection
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00084149|
Recruitment Status : Completed
First Posted : June 8, 2004
Last Update Posted : July 29, 2013
Cyclosporine A (CsA) is a common long-term treatment used to inhibit the immune response in transplant patients who receive donor organs. CsA may also help people with HIV. The purpose of this study is to determine the safety of and immune response to CsA when given with abacavir sulfate, lamivudine, and zidovudine (ABC/3TC/AZT) and lopinavir/ritonavir (LPV/r) to HIV infected adults in the early stages of infection.
Study hypothesis: The combination of CsA and LPV/r given to acutely infected individuals will result in lower levels of proviral DNA and latent infectious virus at 48 weeks compared to acute infected individuals treated with LPV/r alone.
|Condition or disease||Intervention/treatment||Phase|
|HIV Infections||Drug: Abacavir sulfate, Lamivudine, and Zidovudine Drug: Lopinavir/Ritonavir||Phase 2|
During the early stages of HIV infection, HIV replicates unchecked, massive numbers of CD4 T cells are infected and destroyed, and other CD4 cells become infected but enter a latent phase. This latent pool of infected CD4 cells poses a difficult challenge in eliminating HIV infection during the early stages of infection because the cells persist for long periods, even with highly active effective antiretroviral therapy, and may later become active.
CsA is popularly used as a lifelong immunosuppressant for organ transplant patients. CsA inhibits cellular activation, including CD4 cell activation and proliferation. By reducing CD4 cell activation during acute HIV infection, fewer CD4 cells may be infected and die; more importantly, there may be fewer latent cells with the potential to become active later in the disease. However, CsA has many potential toxic effects, including renal damage, and may affect neurologic, endocrine, and hepatic organ systems.
In a previous small study of adults with acute HIV infection, a short 8-week course of CsA was well tolerated, and it is thought that a 4-week course of CsA may result in substantial reduction in both viral load and T cell activation, outweighing any potential toxic effects sustained during the one month treatment. This study will evaluate the safety of and immune response to a 4-week course of CsA with ABC/3TC/AZT and LPV/r compared to ABC/3TC/AZT and LPV/r alone in patients with acute HIV infection.
This 48-week study will randomly assign patients to one of two arms. During the first 4 weeks of the study, Arm A will receive one tablet of ABC/3TC/AZT twice daily, 3 capsules or 2 tablets of LPV/r twice daily, and liquid CsA (dose determined by weight) twice daily. At Week 5, Arm A patients will stop CsA but continue both ABC/3TC/AZT and LPV/r. Arm B will receive one tablet of ABC/3TC/AZT twice daily and 3 capsules or 2 tablets of LPV/r twice daily for all 48 weeks. On a case-by-case basis, an investigator may wish to prescribe ABC/3TC rather than ABC/3TC/AZT at initial therapy. Participants with ABC hypersensitivity will be given 3TC/AZT instead of ABC/3TC/AZT.
A complete physical exam and medical history assessment will occur at study entry and at Week 48. Study visits will occur every week until Week 4, then every 4 weeks until the end of the study. Blood and urine collection and clinical assessments will occur at each study visit. Additionally, patients in Arm A only will undergo CsA level monitoring at Day 3 and Weeks 1, 2, and 3; CsA dosage may be adjusted as necessary.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||16 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Randomized Phase II Study of the Safety, Immunologic, and Virologic Effects of Cyclosporine A in Conjunction With Trizivir(R) and Kaletra(R) Versus Trizivir(R) and Kaletra(R) Alone During Primary HIV-1 Infection|
|Study Start Date :||February 2004|
|Actual Primary Completion Date :||January 2008|
|Actual Study Completion Date :||January 2008|
Arm A will receive one tablet of ABC/3TC/AZT twice daily, 3 capsules or 2 tablets of LPV/r twice daily, and liquid CsA (dose determined by weight) twice daily. At Week 5, Arm A patients will stop CsA but continue both ABC/3TC/AZT and LPV/r.
Drug: Abacavir sulfate, Lamivudine, and Zidovudine
Arm B will receive one tablet of ABC/3TC/AZT twice daily and 3 capsules or 2 tablets of LPV/r twice daily for all 48 weeks
Drug: Abacavir sulfate, Lamivudine, and Zidovudine
- Levels of proviral DNA in PBMC [ Time Frame: At 48 weeks after the start of treatment ]
- Adverse events related to study medication [ Time Frame: Throughout study ]
- Proviral DNA levels [ Time Frame: At Weeks 12 and 24 ]
- Decay of proviral DNA [ Time Frame: Throughout study ]
- HIV-1 viral load levels [ Time Frame: At Weeks 24 and 48 ]
- Percent of patients with viral loads less than 50 copies/ml [ Time Frame: Througout study ]
- Percent of patients with viral loads less than 5 copies/ml [ Time Frame: Throughout study ]
- T cell levels [ Time Frame: At Weeks 2, 4, 8, 12, 24, and 48 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00084149
|United States, Minnesota|
|University of Minnesota, ACTU|
|Minneapolis, Minnesota, United States, 55455-0392|
|United States, New York|
|Beth Israel Med. Ctr., ACTU|
|New York, New York, United States, 10003|
|NY Univ. HIV/AIDS CRS|
|New York, New York, United States, 10016-6481|
|United States, Ohio|
|Cleveland, Ohio, United States, 44109-1998|
|Study Chair:||Martin Markowitz, MD||Aaron Diamond AIDS Research Center|
|Study Chair:||Susan Little, MD||Department of Medicine, University of California at San Diego|